DIAGNOS Delivers World Class Results in the MICCAI2021 Contest: GAMMA
October 28 2021 - 9:00AM
DIAGNOS Inc. (“
DIAGNOS” or “the
Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA:
4D4A), a leader in early detection of certain critical health
issues, announces that its AI platform has delivered world-class
results in the GAMMA (Glaucoma grAding from Multi-Modality imAges)
contest, held in conjunction with The Medical Image Computing and
Computer-Assisted Intervention Society 2021 (MICCAI2021)
conference.
In total 566 teams from around the world
participated in this competition where three (3) AI-driven tasks
were being evaluated.
1) Grading glaucoma using multi-modality data.
(DIAGNOS placed 8th
overall)
In this task, the teams aimed to analyze
clinical data of two modalities, 2D fundus images and 3D OCT
scanning volumes, and classify the samples into three categories
according to visual features: no glaucoma, early glaucoma, and
moderate or advanced glaucoma. DIAGNOS was the only one, of
the top 8 teams, that competed with a marketed, commercialized
system. DIAGNOS used the same platform that it currently uses for
diabetic retinopathy screening, which is marketed worldwide, while
the others were principally from academic
institutions.
2) Localization of macula fovea in fundus
images. (DIAGNOS placed 1st
overall)
The objective of this task was to predict the
coordinate value of the fovea in the 2D fundus image. Localizing
the fovea with high accuracy in colour fundus photographs is very
important. It is the anatomical landmark in automated analysis of
retinal diseases.
3) Segmentation of optic disc and cup in fundus
images. (DIAGNOS placed 1st
overall)
The purpose of this task was to segment the
optic disc and cup region in 2D fundus images. The optic disc and
optic cup segmentation are used to separate these two parts of the
retinal image. It allows the calculation of the cup/disc ratio for
diagnosing glaucoma as well as for monitoring it.
"We are extremely pleased with our performance
in this competition which brought together 566 participating teams
from around the world. This achievement places DIAGNOS at the top
of Artificial Intelligence companies as we continue to be cutting
edge technology leaders for the detection of major retinal
pathologies," said Mr. Riadh Kobbi, Vice-President -
Business Intelligence at DIAGNOS.
“This type of high calibre competition resembles
the Olympics. When you position yourself on the podium, among more
than 500 international teams, it is no accident. This is the result
of many years of hard work and the accumulation of advanced
knowledge in AI,” said Mr. Ismail Ben Ayed, associate
professor at ETS (Ecole de Technologie Supérieure).
"We are very proud to have established a strong
technical team at DIAGNOS to be able to compete worldwide in the
Artificial Intelligence space. This is a world-class competition.
AI-driven analysis of retina Fundus images and OCT (Optical
Coherence Tomography) images is the new medical standard in the
detection and monitoring of serious vision-threatening diseases. At
DIAGNOS, we are investing heavily in R&D and in our strategic
alliance with ETS (Ecole de Technologie Supérieure) to maintain our
leadership in this space. Delivering top-tier results in this
competition demonstrates DIAGNOS’ technical excellence," explained
Mr. André Larente, CEO of DIAGNOS.
About MICCAIThe Medical Image
Computing and Computer-Assisted Intervention Society (the MICCAI
Society) is dedicated to the promotion, preservation and
facilitation of research, education and practice in the field of
medical image computing and computer-assisted medical interventions
including biomedical imaging and medical robotics. The Society
achieves this aim through the organization and operation of annual
high-quality international conferences, workshops, tutorials and
publications that promote and foster the exchange and dissemination
of advanced knowledge, expertise and experience in the field
produced by leading institutions and outstanding scientists,
physicians and educators around the world. The MICCAI Society is
committed to maintaining high academic standards and independence
from any personal, political or commercial interests.
Additional information is available at
http://www.miccai.org/
About the GAMMA ChallengeThe
GAMMA Challenge is an international ophthalmology competition held
by Baidu at the MICCAI2021 seminar OMIA8. MICCAI is a comprehensive
academic conference in the fields of medical image computing and
computer-assisted intervention and is the top conference in these
fields. OMIA is an Ophthalmic Medical Image Analysis seminar
organized by Baidu at the MICCAI conference, which has been held
for eight sessions so far.
Additional information available at:
https://aistudio.baidu.com/aistudio/competition/detail/90/0/introduction
Competition results:
https://aistudio.baidu.com/aistudio/competition/detail/90/0/submit-result
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com.
This press release contains forward-looking
information. We cannot guarantee that the forward-looking
information mentioned will prove to be accurate, as there may be a
significant discrepancy between actual results or future events and
those mentioned in this statement. DIAGNOS disclaims any intention
or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise. The forward-looking information contained in this
press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
Email: alarente@diagnos.ca
Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1604-507-3377
TF: 1-866-503-3377
Email: nancy@irprocommunications.com
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024